Liquidia (NASDAQ:LQDA) Now Covered by Wells Fargo & Company

Wells Fargo & Company started coverage on shares of Liquidia (NASDAQ:LQDAFree Report) in a report released on Friday, MarketBeat.com reports. The firm issued an overweight rating and a $20.00 price target on the stock.

Other equities analysts have also issued research reports about the company. Scotiabank began coverage on Liquidia in a report on Wednesday, October 16th. They set a “sector outperform” rating and a $30.00 price target on the stock. HC Wainwright reiterated a “buy” rating and issued a $29.00 target price on shares of Liquidia in a research note on Thursday, November 14th. Needham & Company LLC reissued a “buy” rating and issued a $19.00 target price on shares of Liquidia in a report on Thursday, November 14th. Finally, Lifesci Capital assumed coverage on Liquidia in a report on Thursday, October 3rd. They set an “outperform” rating and a $30.00 price target for the company. One research analyst has rated the stock with a hold rating, six have issued a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $25.38.

View Our Latest Stock Report on LQDA

Liquidia Stock Performance

Liquidia stock opened at $11.10 on Friday. The stock has a 50-day simple moving average of $10.91 and a 200-day simple moving average of $11.14. The company has a market capitalization of $939.47 million, a P/E ratio of -6.81 and a beta of 0.22. Liquidia has a fifty-two week low of $8.26 and a fifty-two week high of $16.99.

Insider Transactions at Liquidia

In related news, insider Rajeev Saggar sold 2,526 shares of the company’s stock in a transaction that occurred on Friday, October 18th. The stock was sold at an average price of $11.19, for a total value of $28,265.94. Following the sale, the insider now owns 204,857 shares in the company, valued at $2,292,349.83. This represents a 1.22 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Roger Jeffs sold 8,053 shares of the business’s stock in a transaction on Monday, October 14th. The stock was sold at an average price of $11.11, for a total value of $89,468.83. Following the sale, the chief executive officer now owns 812,193 shares in the company, valued at approximately $9,023,464.23. The trade was a 0.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 22,007 shares of company stock valued at $245,780 in the last ninety days. 30.10% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Barclays PLC increased its position in Liquidia by 265.0% during the third quarter. Barclays PLC now owns 99,984 shares of the company’s stock worth $999,000 after buying an additional 72,591 shares in the last quarter. Anson Funds Management LP acquired a new stake in shares of Liquidia during the third quarter valued at $1,764,000. XTX Topco Ltd purchased a new stake in Liquidia during the 3rd quarter worth about $323,000. Wellington Management Group LLP raised its stake in Liquidia by 12.5% in the 3rd quarter. Wellington Management Group LLP now owns 179,923 shares of the company’s stock valued at $1,799,000 after purchasing an additional 19,932 shares during the last quarter. Finally, Whitefort Capital Management LP raised its stake in Liquidia by 119.8% in the 3rd quarter. Whitefort Capital Management LP now owns 1,702,025 shares of the company’s stock valued at $17,020,000 after purchasing an additional 927,546 shares during the last quarter. 64.54% of the stock is currently owned by institutional investors and hedge funds.

About Liquidia

(Get Free Report)

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).

Featured Articles

Analyst Recommendations for Liquidia (NASDAQ:LQDA)

Receive News & Ratings for Liquidia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Liquidia and related companies with MarketBeat.com's FREE daily email newsletter.